{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=86", "query": { "condition": "Advanced Malignancy", "page": 86 }, "page_size": 10 }, "pagination": { "page": 86, "page_size": 10, "total_count": 9818, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=87&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=85&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T09:16:01.874Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01609127", "title": "Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Non-resectable Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Tesetaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genta Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 213, "start_date": "2012-05", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2012-06-01", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01609127" }, { "nct_id": "NCT02713386", "title": "Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "FIGO Stage III Ovarian Cancer 2014", "FIGO Stage IIIA Ovarian Cancer 2014", "FIGO Stage IIIA1 Ovarian Cancer", "FIGO Stage IIIA2 Ovarian Cancer", "FIGO Stage IIIB Ovarian Cancer 2014", "FIGO Stage IIIC Ovarian Cancer 2014", "FIGO Stage IVA Ovarian Cancer 2014", "FIGO Stage IVB Ovarian Cancer 2014", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Endometrioid Adenocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Stage III Fallopian Tube Cancer AJCC v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 147, "start_date": "2016-11-14", "completion_date": "2024-05-22", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 110, "location_summary": "Goodyear, Arizona • Auburn, California • Los Angeles, California + 87 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713386" }, { "nct_id": "NCT00720941", "title": "Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1110, "start_date": "2008-08-14", "completion_date": "2021-03-24", "has_results": true, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 96, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 82 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720941" }, { "nct_id": "NCT01976741", "title": "Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Rogaratinib (BAY1163877) oral solution", "type": "DRUG" }, { "name": "Rogaratinib (BAY1163877) oral tablet", "type": "DRUG" }, { "name": "Rogaratinib (BAY1163877) 800 mg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2013-12-30", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 3, "location_summary": "Chicago, Illinois • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01976741" }, { "nct_id": "NCT02498613", "title": "A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Stage III Breast Cancer AJCC v7", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage III Lung Small Cell Carcinoma AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Small Cell Carcinoma AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Small Cell Carcinoma AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Small Cell Carcinoma AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Triple-Negative Breast Carcinoma", "Unresectable Lung Small Cell Carcinoma", "Unresectable Pancreatic Adenocarcinoma", "Unresectable Pancreatic Carcinoma", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "18F-Fluoromisonidazole", "type": "OTHER" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2016-08-31", "completion_date": "2027-04-10", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 14, "location_summary": "La Jolla, California • Sacramento, California • San Diego, California + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02498613" }, { "nct_id": "NCT01117623", "title": "Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg", "type": "DRUG" }, { "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg", "type": "DRUG" }, { "name": "HCC Child-Pugh A expansion cohort: Regorafenib 100 mg", "type": "DRUG" }, { "name": "HCC Child-Pugh B expansion cohort: Regorafenib 100 mg", "type": "DRUG" }, { "name": "NSCLC expansion cohort: Regorafenib 100 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2007-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117623" }, { "nct_id": "NCT04349280", "title": "A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Bintrafusp alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-10-15", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 2, "location_summary": "Lake Success, New York • Cincinnati, Ohio", "locations": [ { "city": "Lake Success", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04349280" }, { "nct_id": "NCT00004103", "title": "Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "floxuridine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-07", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2011-04-06", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004103" }, { "nct_id": "NCT00006006", "title": "Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2000-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006006" }, { "nct_id": "NCT06390852", "title": "Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Larotrectinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-08-21", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-10T09:16:01.874Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06390852" } ] }